|
Malignant neoplasm of breast
|
0.370 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Meconium Aspiration Syndrome
|
0.210 |
Biomarker
|
phenotype |
MGD |
|
|
|
|
Congenital anomaly of cartilage
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Osteochondrodysplasias
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Epstein-Barr Virus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells.
|
15830149 |
2005 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Atf-2(-/-) MEFs also had a higher saturation density than wild-type cells and expressed lower levels of Maspin, the breast cancer tumor suppressor, which is also known to enhance cellular sensitivity to apoptotic stimuli.
|
17189429 |
2007 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
ATF-2 simultaneously binds to Oct-1, NF-I and breast cancer suppressor BRCA1 to activate transcription.
|
17700520 |
2008 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
ATF-2 simultaneously binds to Oct-1, NF-I and breast cancer suppressor BRCA1 to activate transcription.
|
17700520 |
2008 |
|
Head and Neck Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Activating transcription factor-2 in survival mechanisms in head and neck carcinoma cells.
|
21990224 |
2011 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Activating transcription factor-2 (ATF2) is associated with tumor progression but is not well studied in head and neck squamous cell carcinoma (HNSCC).
|
21990224 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Skin Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
ATF2 has been implicated in a transcriptional response leading to cell migration and malignant tumor progression.
|
23591579 |
2013 |
|
synovial sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATF2 assembles into a complex with the synovial sarcoma translocation, chromosome 18 (SS18)-synovial sarcoma, X breakpoint (SSX) fusion oncoprotein, and the transducin-like enhancer of split 1 (TLE1) corepressor, driving oncogenesis in synovial sarcoma.
|
24289970 |
2014 |
|
Adult Synovial Sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATF2 assembles into a complex with the synovial sarcoma translocation, chromosome 18 (SS18)-synovial sarcoma, X breakpoint (SSX) fusion oncoprotein, and the transducin-like enhancer of split 1 (TLE1) corepressor, driving oncogenesis in synovial sarcoma.
|
24289970 |
2014 |
|
Childhood Synovial Sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATF2 assembles into a complex with the synovial sarcoma translocation, chromosome 18 (SS18)-synovial sarcoma, X breakpoint (SSX) fusion oncoprotein, and the transducin-like enhancer of split 1 (TLE1) corepressor, driving oncogenesis in synovial sarcoma.
|
24289970 |
2014 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
ATF2 may therefore play an important role in the oncogenesis of many mesenchymal tumors, but as yet, little is known about its protein expression in patient specimens.
|
24289970 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activating transcription factor-2 (ATF-2) has been implicated as a tumour suppressor in breast cancer (BC). c-JUN N-terminal kinase (JNK) and p38 MAPK phosphorylate ATF-2 within the activation domain (AD), which is required for its transcriptional activity.
|
25141981 |
2014 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
ATF2 knockdown and overexpression studies were performed in RCC cells to evaluate changes in cell viability, cell cycle, apoptosis, migration and invasion.
|
27377902 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Activating transcription factor 2 (ATF2) is a multifunctional transcription factor, and is implicated in tumor progress, yet its role in pancreatic cancer remains unclear.
|
28318081 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
ATF2 is a basic leucine zipper protein and is involved in physiological and developmental processes, as well as in tumorigenesis.
|
31799611 |
2019 |
|
Neonatal encephalopathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A neonatal encephalopathy with seizures in standard poodle dogs with a missense mutation in the canine ortholog of ATF2.
|
18074159 |
2008 |